The REPROCELL Blog

Press Release: ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

From Frying-Pan to Fire

The Human Touch: meeting clinical needs in IBD research

New publication by Roche on diarrheal toxicity induced by anti-HER2/3 combination therapy includes REPROCELL human fresh tissue data

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

Join REPROCELL at ISSCR 2018 in Melbourne, Australia

REPROCELL's footprint extends to serve life sciences in India

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

Factors to consider when planning a iPSC reprogramming project

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

Characterization of iPSCs by Immunocytochemistry

The Benefits of Human Tissue to Drug Discovery and Development

REPROCELL’s David Bunton addresses the Scottish Parliament

Patient-derived tumor organoids recapitulated clinical treatments

Five reasons to choose StemRNA 3rd Gen reprogramming

Inserts or Plates: Which format for your 3D cell culture

Cost Effective, Lab-scale iPS Cell Spheroid Culture

Xeno-free culture of pluripotent stem cells in NutriStem® hPSC XF medium

REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018

Formation of human tissue to improve drug testing and reduce animal research

The Power of One Brand